Teva Pharmaceuticals, the Israel based generic major, has reportedly settled its patent litigation with the Ahmedabad-based Cadila Healthcare and its US-based subsidiary Zydus Pharmaceuticals Inc concerning the process of making carvedilol
First of all Teva sent enquiry letters to lot of companies and then sued some of them in round one and followed by the settlement. Teva purportedly settled first with DRL then Cadila and Torrent; but later, they sued a whole bunch of companies excluding DRL in round 2 including some of those who had settled in 1st round.
Teva has sent enquiry letters to some companies for Carvedilol and has already sued Zentiva for the same. This action should be worrying for other generic companies that are about to enter Carvedilol space
Teva is the drug manufacturer for the technology that goes into manufacturing carvedilol. The other companies included Ranbaxy Laboratories, Cadila Healthcare, Lupin and Orchid Chemicals. But Teva went ahead and withdrew the case against Dr Reddy’s as Dr Reddy’s had asked for a summary judgement from the New Jersey District Court. Now once the core patent against which Dr Reddy’s was sued is withdrawn by Teva, Dr Reddy’s will be able to sell this particular drug. It’s quite a big drug; now Zydus is also in the big list of Teva for the settlement.
Originally it is licensed by Roche to GSK in the US and it’s a very strong product as far as Teva is concerned. So there will be hindrances put by Teva for any other company which want to market that product.
It should be noted that the market size of the carvedilol would be upwards of USD 400 million.
So, war will be continued with other giants……..
